Seres Therapeutics (MCRB) Stock Spikes in Initial Public Offering

NEW YORK (TheStreet) -- Seres Therapeutics  (MCRB) shares are gaining, up 91.72% to $34.51, in the biotech company's first day of trading on the Nasdaq.

The Cambridge, MA-based company priced its upsized public offering of 7.43 million shares at $18 per share.

The company had previously said that it would offer 6.25 million shares between the $15 and $17 per share range.

Seres Therapeutics' lead development candidate, SER-109, is an oral therapeutic for the prevention of Clostridium difficile infection which affects between 85,000 and 110,000 people in the U.S.

The drug candidatite is currently in Phase II trials.

The company also has five other drug candidates in its development pipeline at various trial stages

MCRB Price Chart MCRB Price data by YCharts

More from Markets

Video: Jim Cramer Reveals Why Stocks Are Moving Lower Thursday

Video: Jim Cramer Reveals Why Stocks Are Moving Lower Thursday

Dow Falls, S&P 500 Lower as Amazon Rises, Apple and P&G Slump

Dow Falls, S&P 500 Lower as Amazon Rises, Apple and P&G Slump

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options